

Longitudinal monitoring of anti-SARS-CoV-2 RBD IgG antibodies after BNT162b2 vaccination in healthcare workers

Gian Luca Salvagno^{1,2}, Brandon M. Henry^{3,4}, Laura Pighi^{1,2}, Simone De Nitto^{1,2}, Gianluca Gianfilippi⁵, Giuseppe Lippi¹

¹Section of Clinical Biochemistry, University of Verona, Verona, Italy

²Service of Laboratory Medicine, Pederzoli Hospital, Peschiera del Garda, Italy

³Clinical Laboratory, Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

⁴Disease Intervention & Prevention and Population Health Programs, Texas Biomedical Research Institute, San Antonio, Texas, USA

⁵Medical Direction, Pederzoli Hospital, Peschiera del Garda, Italy

Keywords: COVID-19, SARS-CoV-2, vaccination, antibodies, immune response

To the Editor,

Nearly two years after the origin of the ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, the race to develop and distribute effective coronavirus diseases 2019 (COVID-19) vaccines continues. Recent evidence suggests that the clinical efficacy of the COVID-19 vaccines currently cleared by EMA (European Medicines Agency) is as high as 80-100% shortly after administration (1), though a significant decline of efficacy after several months, especially in preventing symptomatic COVID-19 illness, has been recently demonstrated (2). This evidence leads the way to using additional vaccine boosters, usually to be administered 6 months after completing a standard vaccination cycle (3), and is supported by reliable laboratory data, demonstrating that vaccine efficacy depends on anti-SARS-CoV-2 neutralizing antibody levels (1), whose values tend to naturally wane over time (4,5). This study was hence aimed to provide further insights on the kinetics of anti-SARS-CoV-2 IgG neutralizing antibodies elicited by COVID-19 vaccination in healthcare workers and their potential correlation with vaccine efficacy.

We initially enrolled 100 healthcare workers of the Hospital of Peschiera del Garda (Italy), all SARS-CoV-2 seronegative, who voluntarily received COVID-19 vaccination with Pfizer/BioNTech BNT162b2 (Comirnaty, Pfizer Inc., New York, NY, US; 30 µg in two doses, 3 weeks apart). Serum samples were collected before all subjects received the first and second BNT162b2 vaccination, and then 1, 3 and 6 months after the second BNT162b2 dose. Serum values of anti-SARS-CoV-2 RBD (receptor binding domain) IgG antibodies were measured with ACCESS SARS-CoV-2 IgG II (Beckman Coulter Inc., Brea, CA, US). This method is a paramagnetic particle, chemiluminescent immunoassay, excellently correlated with a surrogate virus neutralization test ($r=0.96$; $p < 0.001$), and with sensitivity and specificity for detecting previous SARS-CoV-2 infections, both approaching 100% (6). Results of measurements were reported in terms of antibodies units (AU)/mL (this method is not traceable to the World Health Organization standard), expressed as median and interquartile range (IQR). Effectiveness of BNT162b2 vaccination in eliciting a significant and durable humoral response in our population was defined as an anti-SARS-CoV-2 RBD IgG antibodies level ≥ 10 AU/mL, in keeping with manufacturer's recommendations. Further technical and analytical characteristics of this assay are reported elsewhere (7). All our study subjects provided a written informed consent for undergoing BNT162b2 vaccination and long-term serological monitoring. The study was performed in accordance with the Helsinki Declaration and approved by the Ethics Committee of the Provinces of Verona and Rovigo (59 COVIDCESC; November 3, 2021).

The final study population included 86 SARS-CoV-2 baseline seronegative subjects, with a median age of 45 years (IQR 31-53 years; 47.7% males), while 14 subjects were lost to follow-up over the 6-month study period.

Corrispondenza a: Giuseppe Lippi, Section of Clinical Biochemistry, University Hospital of Verona, Piazzale L.A. Scuro, 10 37134 Verona - Italy, Tel 0039-045-8122970, Fax 0039-045-8124308, Email giuseppe.lippi@univr.it

Ricevuto: 12.11.2021

Revisionato: 15.11.2021

Accettato: 16.11.2021

Publicato on-line: 24.11.2021

DOI: 10.19186/BC_2021.074




Figure 1
 Longitudinal monitoring of anti-SARS-CoV-2 RBD (receptor binding domain) IgG serum levels in seronegative healthcare workers undergoing BNT162b2 mRNA-based vaccine administration. The dashed line delineates the manufacturer's recommended threshold of antibodies positivity (i.e., ≥ 10 AU/mL).

*After the second vaccine dose




Figure 2
 Rate of BNT162b2 vaccine recipients displaying with anti-SARS-CoV-2 RBD (receptor binding domain) IgG serum levels ≥ 10 AU/mL, which corresponds to the antibodies positivity threshold defined by the manufacturer.

*After the second vaccine dose

The results of anti-SARS-CoV-2 RBD IgG antibodies up to 6 months after completing the 2nd BNT162b2 vaccine dose is reported in Figure 1, showing that the serum levels of these antibodies reached a peak of 344.4 AU/mL (IQR, 216.7-542.2 AU/mL) 1 month after the second vaccine dose, but then declined to 70.6 AU/mL (IQR, 41.8-112.0 AU/mL) and further to 17.6 AU/mL (IQR, 9.7-27.3 AU/mL) at 3 and 6 months after the second vaccine dose, respectively. Such reductions correspond to a median decrease from the peak of -79.3% (IQR, -76.5 – -82.6%) and

-95.3% (IQR, -93.3 – -96.4%) at 3 and 6 months after the second vaccine dose, respectively. The overall rate of BNT162b2 vaccine recipients displaying serum anti-SARS-CoV-2 RBD IgG antibodies levels above the 10 AU/mL threshold is shown in Figure 2. Briefly, the rate increased from 0/86 (0%) at baseline (all subjects were SARS-CoV-2 seronegative), to 77/86 (89.5%) and 85/86 (98.8%) after the first and second BNT162b2 vaccine doses, remained stable up to 3 months after the second vaccine dose (85/86; 98.8%), but then declined to 60/86 (69.8%) when anti-SARS-CoV-2 RBD IgG antibodies were assayed 6 months after the second vaccine dose. Notably, it is not surprising that the only subject who remained seronegative (i.e., anti-SARS-CoV-2 RBD IgG antibodies levels <10 AU/mL) throughout the study period was a 70-year old man, since vaccine reactogenicity is reportedly lower in older male people (8,9).

In keeping with previous evidence from other countries, populations and settings (4,5), the results of this study on Italian healthcare workers who underwent administration of BNT162b2 mRNA-based COVID-19 vaccine suggest that humoral immunity and, more specifically, the serum levels of anti-SARS-CoV-2 RBD IgG antibodies, displayed a dramatic decay 6 months after vaccination, with values 95,3% lower than those measured at the peak, with nearly 30% of subjects displaying antibodies levels below the recommended threshold of positivity (i.e., <10 AU/mL). This data suggests that nearly one-third of BNT162b2 vaccine recipients have an insufficient value of serum anti-SARS-CoV-2 RBD IgG antibodies at 6 months post-vaccination. Intuitively, this finding goes hand in hand with the evidence that the rate of breakthrough SARS-CoV-2 infections in COVID-19 vaccine recipients increases over time and is strongly correlated with the level of anti-SARS-CoV-2 RBD IgG antibodies (10), as well as provides additional support to the importance of SARS-CoV-2 serologic monitoring before administration of vaccine boosters. This strategy would allow to timely identify those in whom the neutralizing antibodies have waned faster, have become more vulnerable to infection and disease, and shall hence be prioritized for receiving additional vaccine boosters in the future (8,9).

Acknowledgments

The authors are thankful to the entire staff of the Pederzoli Hospital of Peschiera del Garda (Verona, Italy) for accepting to participate to this study.

CONFLICT OF INTEREST

None.

REFERENCES

1. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med* 2021;27:1205-11.
2. Chemaiteilly H, Tang P, Hasan MR, et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. *N Engl J Med* 2021 NEJMoa2114114 doi: 10.1056/NEJMoa2114114.
3. Sarpatwari A, Pandya A, Hyle EP, et al. COVID-19 Vaccine boosters for all adults: an optimal U.S. approach? *Ann Intern Med* 2021 doi: 10.7326/M21-3927.
4. Bayart JL, Douxfils J, Gillot C, et al. Waning of IgG, total and neutralizing antibodies 6 months post-vaccination with BNT162b2 in healthcare workers. *Vaccines (Basel)* 2021;9:1092.
5. Naaber P, Tserel L, Kangro K, et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. *Lancet Reg Health Eur* 2021;10:100208.
6. Kitagawa Y, Imai K, Matsuoka M, et al. Evaluation of the correlation between the access SARS-CoV-2 IgM and IgG II antibody tests with the SARS-CoV-2 surrogate virus neutralization test. *J Med Virol* 2021 doi: 10.1002/jmv.27338.
7. Ruscio M, D'Agnolo E, Belgrano A, et al. Analytical assessment of Beckman Coulter Access anti-SARS-CoV-2 IgG immunoassay. *J Lab Precis Med* 2021;6:3.
8. Lippi G, Henry BM, Plebani M. Optimizing effectiveness of COVID-19 vaccination: will laboratory stewardship play a role? *Clin Chem Lab Med* 2021;59:1885-8.
9. Plebani M, Banfi G, Lippi G. Valutazione della risposta anticorpale post-vaccino COVID-19: fiat lux. *Biochim Clin* 2021;45:228-9.
10. Blain H, Tuailon E, Gamon L, et al. Receptor binding domain-IgG levels correlate with protection in residents facing SARS-CoV-2 B.1.1.7 outbreaks. *Allergy* 2021 doi: 10.1111/all.15142.